

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Silvia Salvadori on 7-30-09.

The application has been amended as follows:

Claim 116, line 31 "an alkyl chain selected from the group consisting of" and "and tetradecyl" following the word 'undecyl' have been deleted. The expression, "the molar ratio between the compound of the formula (II) and the taxol or the camptothecin is 40:1; and" has been added after 'undecyl; '

Claim 117, "acid aspartate;" and 'acid" on line 2, "citrate;" , "acid tartrate;" , "acid phosphate;" , "acid fumarate;" on line 3, "acid maleate;" on line 4, "acid oxalate" , "acid sulphate;" on line 5 have been deleted.

After the term, 'methane sulphonate;' on line 5, the term, "and" has been added.

On line 6, "and acid pamoate' has been deleted.

Claim 118: line 3, 'and' has been added before 'stearoyl. ";stearoyl L carnitine chloride tetradecyl ester; palmitoyl L carnitine chloride tetradecyl ester' on lines 3 and 4 has been deleted.

Claim 122: lines 5, “an alkyl chain selected from the group consisting of” and “and tetradecyl” following the word ‘undecyl’ have been deleted. On the last line of claim 122, after ‘the pharmaceutically acceptable salts thereof’, “the molar ratio between the compound of the formula (II) and the taxol or the camptothecin is 40:1.” has been added.

Claim 123: “acid aspartate;” on line 2, “acid citrate”, “acid tartrate;”, “acid phosphate;”, “acid fumarate;” on line 3, “acid maleate;” on line 4, “acid oxalate”, “acid sulphate;” on line 5 have been deleted.

After the term, ‘methane sulphonate;’ on line 5, the term, “and” has been added.

On line 6, “and acid pamoate’ has been deleted.

Claim 124: line 3, ‘and’ has been added before ‘stearoyl. “;stearoyl L carnitine chloride tetradecyl ester; palmitoyl L carnitine chloride tetradecyl ester’ on lines 3 and 4 has been deleted.

Claim 128: line 33 “an alkyl chain selected from the group consisting of” and “and tetradecyl” following the word ‘undecyl’ have been deleted. The expression, “the molar ratio between the compound of the formula (II) and the taxol or the camptothecin is 40:1; and” has been added after ‘undecyl;’.

Claim 129: “acid aspartate;” and ‘acid” on line 2, “citrate;”, “acid tartrate;”, “acid phosphate;”, “acid fumarate;” on line 3, “acid maleate;” on line 4, “acid oxalate”, “acid sulphate;” on line 5 have been deleted.

After the term, 'methane sulphonate;' on line 5, the term, "and" has been added.

On line 6, "and acid pamoate" has been deleted.

Claim 130: line 3, 'and' has been added before 'stearoyl. ";stearoyl L carnitine chloride tetradecyl ester; palmitoyl L carnitine chloride tetradecyl ester' on lines 3 and 4 has been deleted.

Claim 147: line 34 "an alkyl chain selected from the group consisting of" and "and tetradecyl" following the word 'undecyl' have been deleted. The expression, "the molar ratio between the compound of the formula (II) and the taxol or the camptothecin is 40:1; and" has been added after 'undecyl;'.

Claim 148:, "acid aspartate;" and "acid" on line 2, "citrate;", "acid tartrate;", "acid phosphate;", "acid fumarate;" on line 3, "acid maleate;" on line 4, "acid oxalate", "acid sulphate;" on line 5 have been deleted.

After the term, 'methane sulphonate;' on line 5, the term, "and" has been added.

On line 6, "and acid pamoate" has been deleted.

Claim 149: line 3, 'and' has been added before 'stearoyl. ";stearoyl L carnitine chloride tetradecyl ester; palmitoyl L carnitine chloride tetradecyl ester' on lines 3 and 4 has been deleted.

Claim 156: lines 34-36: "or iii. R3 is stearoyl and R4 is tetradecyl; or iv. R3 is palmitoyl and R4 is undecyl;" has been deleted. The expression, "the molar ratio

Art Unit: 1612

between the compound of the formula (II) and the taxol or the camptothecin is 40:1; and" has been added after 'undecyl;'.

Claim 157: "acid aspartate;" and 'acid" on line 2, "citrate;" , "acid tartrate;" , "acid phosphate;" , "acid fumarate;" on line 3, "acid maleate;" on line 4, "acid oxalate" , "acid sulphate;" on line 5 have been deleted.

After the term, 'methane sulphonate;' on line 5, the term, "and" has been added.

On line 6, "and acid pamoate' has been deleted.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gollamudi S. Kishore whose telephone number is (571) 272-0598. The examiner can normally be reached on 6:30 AM- 4 PM, alternate Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Krass Frederick can be reached on (571) 272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1612

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Gollamudi S Kishore/
Primary Examiner, Art Unit 1612

GSK